(AOF) – Median Technologies generated a turnover of 22.2 million euros in 2023, a decline of 6.7% compared to 23.7 million euros in 2022. The medtech specialist in solutions and services imaging specifies that its 2023 turnover was impacted by “the stagnation of order intake in China linked to Covid confinements during the second half of 2022 and the first half of 2023”. The company expects double-digit growth in turnover and order book in 2024, driven by the recovery in China and the acceleration of activity in the United States.
Median announces that as of December 31, 2023, its cash and cash equivalents stood at 19.5 million euros, compared to 21.5 million as of December 31, 2022, after the collection in January 2024 of 8, 5 million corresponding to the release of the last tranche of the loan taken out with the European Investment Bank (EIB) in December 2019.
Median underlines that its order book reached its all-time high in 2023 at 66.9 million euros, driven by a record order intake in the fourth quarter of 2023. It is up 10% year-on-year.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.